CD14＋HLA-DRLow/-髓源抑制性细胞样细胞与白细胞介素1β在卵巢癌中的表达及相关性  

The expression and association of CD14 ＋ HLA-DRLow/-myeloid-derived suppressor cell-like cells and interleukin-1β in ovarian cancer

作　　者：王华阳[1] 赵睿[1] 任浩[1] 邹明瑾[1] 张建[1] 张义[1] 

机构地区：[1]山东大学齐鲁医院检验科,济南250012

出　　处：《中华医学杂志》2017年第34期2663-2669,共7页National Medical Journal of China

基　　金：基金项目：山东省重点研发计划（2016GSF201122）;山东省重点研发计划（产业关键技术）（2016CYJS01A02）;山东大学横向课题（26010111671703）

摘　　要：目的 分析卵巢癌患者外周血及腹水CD14＋ HLA-DRLow/-髓源抑制性细胞（MDSCs）样细胞与白细胞介素1β（IL-1β）的表达水平,探讨与卵巢癌临床病理特征的相关性.方法 收集2016年1至12月山东大学齐鲁医院31例卵巢癌患者外周血,从中选取5例中晚期患者留取腹腔积液.收集同一时期年龄构成相匹配的20名健康志愿者外周血作为对照.流式细胞术分析卵巢癌患者外周血、腹腔积液以及健康对照者外周血中CD14＋ HLA-DRLow/-细胞亚群在CD14＋单核细胞中所占比例并分离获取该群细胞.流式细胞术分析CD14＋ HLA-DRLow/-细胞亚群表型,实时定量PCR检测该群细胞免疫抑制因子表达情况.酶联免疫吸附法检测卵巢癌患者外周血、腹腔积液以及健康对照者外周血中IL-1 β表达水平,并与CD14＋ HLA-DRLow/-细胞所占比例进行相关性分析.统计卵巢癌患者临床资料,分析CD14＋ HLA-DRLow/-细胞及IL-1β水平与临床病理特征的相关性.结果 健康对照组及卵巢癌患者外周血CD14＋ HLA-DRLow/-细胞在CD14＋单核细胞中所占比例分别为（2.30±0.49）％和（3.74±0.95）％,差异有统计学意义（t =6.96,P＜0.01）,该群细胞表型与因子表达与单核样MDSCs相似.卵巢癌患者腹腔积液中CD14＋ HLA-DRLow/-细胞百分比为（16.60±7.35）％,显著高于外周血的（4.03±0.94）％,差异有统计学意义（t =3.87,P＜0.05）.健康对照组及卵巢癌患者外周血IL-1β水平分别为3.88（0.41,7.07） ng/L及（12.77±3.52） ng/L,差异有统计学意义（Z=-4.93,P＜0.01）.5例卵巢癌患者腹腔积液IL-1β水平为（62.17 ±23.05） ng/L,显著高于外周血的（12.65 ±3.93） ng/L,差异有统计学意义（=5.20,P＜0.01）.卵巢癌患者外周血及腹腔积液IL-1β表达水平与CD14＋ HLA-DRLow/-细胞比例存在相关性（外周血R2 =0.36,P＜0.01;腹腔积液R2=0.68,P＜0.05）,健康对照组外周血IL-1β表达水平与CD14＋ HLA-DRLow/-细胞比例无�Objective To analyze the percentage of CDi4＋ HLA-DRLow/-myeloid-derived suppressor cell-like cell subtypes（MDSCs） and interleukin-1 β（IL-1 β） concentration in peripheral blood and ascites of ovarian cancer patients,and to explore their association with clinicopathological characteristics.Methods Blood samples of 31 patients and ascites of 5 patients in Qilu Hospital of Shandong University from January 2016 to December 2016 were collected.Blood samples of 20 healthy volunteers with matched age were collected as control.The percentages of CD14 ＋ HLA-DRLow/-cell subtypes in CD14 ＋ monocytes were collected by flow cytometry and their phenotypes were analyzed.qRT-PCR was used to analyze the expression of immunosuppression factors in this subtype.ELISA was used to analyze IL-1β concentration in peripheral blood and ascites of ovarian cancer patients and healthy controls.The correlation between CD14 ＋ HLA-DRLow/-cell percentage and IL-1β concentration was explored.The association between CD14 ＋ HLA-DRLow/ cell percentage,IL-1β concentration and clinicopathological characteristics were analyzed.Results The percentage of CD14 ＋ HLA-DRLow/-cells in CD14 ＋ monocytes of peripheral blood of healthy controls was （2.30± 0.49）%,and the percentage in ovarian cancer patients was （3.74 ± 0.95）%,with statistical significance （t =6.96,P 〈 0.01）.This cell subset showed similar phenotypes and factor expression with monocytic MDSCs.The percentage of CD14 ＋ HLA-DRLow/ cells in peripheral blood ascites of ovarian cancer patients was （16.60 ± 7.35） %,significantly higher than those in peripheral bloods （4.03 ± 0.94） % （t =3.87,P 〈0.05）.The concentration of IL-1β in peripheral blood of healthy controls was [3.88 （0.41,7.07）] ng/L,and the concentration in ovarian cancer patients was （12.77 ± 3.52） ng/L,with statistical significance （Z =-4.93,P 〈 0.01）.IL-1β concentration in ascites of ovarian cancer patients was （62.17 ± 23.05） ng/L,significantly higher than t

关 键 词：卵巢肿瘤 髓源抑制性细胞 白细胞介素1Β 肿瘤转移 

分 类 号：R737.31[医药卫生—肿瘤]